Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.55 |
| ▸ | CTSD | P07339 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472988 | 0.89 | BACE1 (0.62) | BACE1CTSD | |
| SCHEMBL4478905 | 0.88 | BACE1 (0.46) | BACE1CTSDKMT2ABACE2ELANE | |
| SCHEMBL4478091 | 0.87 | KDM4E (0.45) | BACE1CTSDKMT2ABACE2KDM4E | |
| SCHEMBL4480903 | 0.87 | BACE1 (0.43) | BACE1CTSDKMT2ABACE2KDM4E | |
| SCHEMBL4491289 | 0.86 | BACE1 (0.65) | BACE1CTSDBACE2 | |
| SCHEMBL5502569 | 0.85 | BACE1 (0.47) | BACE1CTSDBACE2KDM4EALDH1A1 | |
| SCHEMBL4478954 | 0.85 | MAPT (0.46) | BACE1CTSDKMT2AKDM4EALDH1A1 | |
| SCHEMBL5506166 | 0.84 | BACE1 (0.47) | BACE1CTSDBACE2KDM4EALDH1A1 | |
| SCHEMBL4485890 | 0.84 | BACE1 (0.66) | BACE1CTSDBACE2 | |
| Guanidine SCHEMBL5507238 | 0.84 | MAPT (0.45) | BACE1CTSDKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1848692-A1 | AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS | Wyeth (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088711-A1 | AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885CTSD 590/4885KMT2A 634/4885 |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | BACE1, BACE2, APP | BACE1 1/4885CTSD 590/4885KMT2A 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.